Advertisement

Current Urology Reports

, 20:42 | Cite as

Outcomes of Surgery in Peyronie’s Disease Following Intralesional Collagenase Clostridium Histolyticum Injections

  • Mahdi Bazzi
  • Marcus L. Jamil
  • Ali A. DabajaEmail author
Men's Health (A Dabaja, Section Editor)
  • 5 Downloads
Part of the following topical collections:
  1. Topical Collection on Men’s Health

Abstract

Purpose of Review

To explore the potential hurdles surgeons may encounter when preforming surgical correction of penile curvature in patients with Peyronie’s Disease following intralesional collagenase clostridium histolyticum injections.

Recent Findings

Although limited data exists, retrospective analysis of surgeon experiences in surgical treatment of refractory penile curvature in patients with Peyronie’s disease appears to not result in more post-operative complications and may only slightly increase intra-operative difficulty.

Summary

As the use of intralesional collagenase clostridium histolyticum continues to increase and patients who demonstrate persistent curvature despite treatment seek further management, the role of investigating the feasibility of surgery demonstrates significant importance. Although limited data exists, it appears that surgery following intralesional collagenase clostridium histolyticum is safe without added post-operative complications. At the present time, however, further data on intra-operative findings and post-operative outcomes remain necessary, and as the use of this intralesional therapy continues to rise, further information should become readily available.

Keywords

Peyronie’s disease Collagenase clostridium histolyticum Reconstructive surgery Refractory curvature Surgical outcome Sexual medicine 

Notes

Acknowledgments

The authors and editors would like to thank Dr. Bahaa Malaeb, University of Michigan, for providing the review of their manuscript.

Compliance with Ethical Standards

Conflict of Interest

Mahdi Bazzi and Marcus L. Jamil each declare no potential conflicts of interest.

Ali A. Dabaja is a section editor for Current Urology Reports.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Nehra A, et al. Peyronie’s disease: AUA Guideline. J Urol. 2015;194(3):745–53.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Schwarzer U, et al. The prevalence of Peyronie’s disease: results of a large survey. BJU Int. 2001;88(7):727–30.PubMedGoogle Scholar
  3. 3.
    Stuntz M, et al. The prevalence of Peyronie’s disease in the United States: a population-based study. PLoS One. 2016;11(2):e0150157.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Sommer F, et al. Epidemiology of Peyronie’s disease. Int J Impot Res. 2002;14(5):379–83.PubMedGoogle Scholar
  5. 5.
    Shiraishi K, Shimabukuro T, Matsuyama H. The prevalence of Peyronie’s disease in Japan: a study in men undergoing maintenance hemodialysis and routine health checks. J Sex Med. 2012;9(10):2716–23.PubMedGoogle Scholar
  6. 6.
    Terrier JE, Nelson CJ. Psychological aspects of Peyronie’s disease. Transl Androl Urol. 2016;5(3):290–5.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Rosen R, et al. Impact of Peyronie’s disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med. 2008;5(8):1977–84.PubMedGoogle Scholar
  8. 8.
    Nelson CJ, Mulhall JP. Psychological impact of Peyronie’s disease: a review. J Sex Med. 2013;10(3):653–60.PubMedGoogle Scholar
  9. 9.
    Burri A, Porst H. The relationship between penile deformity, age, psychological bother, and erectile dysfunction in a sample of men with Peyronie’s disease (PD). Int J Impot Res. 2018;30(4):171–8.PubMedGoogle Scholar
  10. 10.
    Mulhall JP, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171(6 Pt 1):2350–3.PubMedGoogle Scholar
  11. 11.
    Carrieri MP, et al. A case-control study on risk factors for Peyronie’s disease. J Clin Epidemiol. 1998;51(6):511–5.PubMedGoogle Scholar
  12. 12.
    El-Sakka Ahmed I, Tayeb Khalid A. Peyronie’s disease in diabetic patients being screened for erectile dysfunction. J Urol. 2005;174(3):1026–30.PubMedGoogle Scholar
  13. 13.
    El-Sakka AI, et al. The pathophysiology of Peyronie’s disease. Arab J Urol. 2013;11(3):272–7.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Valenzuela R, et al. The use of penile traction therapy in the management of Peyronie’s disease: current evidence and future prospects. Therapeutic advances in urology, vol. 11; 2019. p. 1756287219838139.Google Scholar
  15. 15.
    La Pera G, et al. Peyronie’s disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol. 2001;40(5):525–30.PubMedGoogle Scholar
  16. 16.
    Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530–5 discussion 535-6.PubMedGoogle Scholar
  17. 17.
    Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie’s disease. Urology. 2007;69(6):1181–4.PubMedGoogle Scholar
  18. 18.
    Smith JF, Shindel AW, Huang YC, Clavijo RI, Flechner L, Breyer BN, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease. Asian J Androl. 2011;13(2):322–5.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Barrett-Harlow B, Wang R. Oral therapy for Peyronie’s disease, does it work? Transl Androl Urol. 2016;5(3):296–302.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Russo GI, Milenkovic U, Hellstrom W, Levine LA, Ralph D, Albersen M. Clinical efficacy of injection and mechanical therapy for Peyronie’s disease: a systematic review of the literature. Eur Urol. 2018;74(6):767–81.PubMedGoogle Scholar
  21. 21.
    Kayes O, Khadr R. Recent advances in managing Peyronie’s disease. F1000Res. 2016;5:F1000 Faculty Rev-2372.Google Scholar
  22. 22.
    Brimley SC, Yafi FA, Greenberg J, Hellstrom WJG, Tue Nguyen HM, Hatzichristodoulou G. Review of management options for active-phase Peyronie’s disease. Sex Med Rev. 2019;7(2):329–37.PubMedGoogle Scholar
  23. 23.
    Levine LA, Larsen SM. Surgical correction of persistent Peyronie’s disease following collagenase clostridium histolyticum treatment. J Sex Med. 2015;12(1):259–64.PubMedGoogle Scholar
  24. 24.
    • DeLay K, et al. Successful treatment of residual curvature in Peyronie disease in men previously treated with intralesional collagenase clostridium histolyticum. Urology. 2017;110:110–3 This retrospective review by DeLay et al. outlines the foundation for the fundamental question in our review; it assesses the safety and outcomes of surgical correction of penile curvature following CCH injections. PubMedGoogle Scholar
  25. 25.
    Yang KK, Bennett N. The history of collagenase clostridium histolyticum. Sex Med Rev. 2015;3(4):289–97.PubMedGoogle Scholar
  26. 26.
    Starkweather KD, Lattuga S, Hurst LC, Badalamente MA, Guilak F, Sampson SP, et al. Collagenase in the treatment of Dupuytren’s disease: an in vitro study. J Hand Surg Am. 1996;21(3):490–5.PubMedGoogle Scholar
  27. 27.
    Badalamente MA, Hurst LC. Enzyme injection as nonsurgical treatment of Dupuytren’s disease. J Hand Surg Am. 2000;25(4):629–36.PubMedGoogle Scholar
  28. 28.
    Shaw RB Jr, Chong AKS, Zhang A, Hentz VR, Chang J. Dupuytren’s disease: history, diagnosis, and treatment. Plast Reconstr Surg. 2007;120(3):44e–54e.PubMedGoogle Scholar
  29. 29.
    Costas B, et al. Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomized controlled trial. BMC Musculoskelet Disord. 2017;18(1):374.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Carson Iii CC, et al. Analysis of the clinical safety of intralesional injection of collagenase clostridium histolyticum (CCH) for adults with Peyronie’s disease (PD). BJU Int. 2015;116(5):815–22.Google Scholar
  31. 31.
    Traore EJ, Wang W, Yafi FA, Hellstrom WJG. Collagenase clostridium histolyticum in the management of Peyronie’s disease: a review of the evidence. Ther Adv Urol. 2016;8(3):192–202.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Cwikla DJ, Yafi FA. Intralesional collagenase Clostridium histolyticum in the management of Peyronie’s disease: current best practice. Ther Adv Urol. 2018;10(4):139–53.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Gelbard M, Goldstein I, Hellstrom WJG, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199–207.PubMedGoogle Scholar
  34. 34.
    Capece M, Cocci A, Russo G, Cito G, Giubilei G, Cacciamani G, et al. Collagenase clostridium histolyticum for the treatment of Peyronie’s disease: a prospective Italian multicentric study. Andrology. 2018;6(4):564–7.PubMedGoogle Scholar
  35. 35.
    Bella AJ, et al. Canadian Urological Association guideline for Peyronie’s disease and congenital penile curvature. Can Urol Assoc J. 2018;12(5):E197–209.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Cayan S et al. Comparison of patient’s satisfaction and long-term results of two penile plication techniques: lessons learned from 387 patients with penile curvature. Urology. 2019.Google Scholar
  37. 37.
    • Wayne GF, Cordon BH. Contemporary surgical and non-surgical management of Peyronie’s disease. Transl Androl Urol. 2018;7(4):603–17 This review article by Wayne et al. outlines many of the commonly performed medical and surgical interventions available to patients afflicted by Peyronie’s disease. PubMedPubMedCentralGoogle Scholar
  38. 38.
    Nesbit RM. Congenital curvature of the phallus: report of three cases with description of corrective operation. J Urol. 1965;93:230–2.PubMedGoogle Scholar
  39. 39.
    Pryor JP, Fitzpatrick JM. A new approach to the correction of the penile deformity in Peyronie’s disease. J Urol. 1979;122(5):622–3.PubMedGoogle Scholar
  40. 40.
    Kadioglu A, Kucukdurmaz F, Sanli O. Current status of the surgical management of Peyronie’s disease. Nat Rev Urol. 2011;8(2):95–106.PubMedGoogle Scholar
  41. 41.
    Devine CJ Jr, Horton CE. Surgical treatment of Peyronie’s disease with a dermal graft. J Urol. 1974;111(1):44–9.PubMedGoogle Scholar
  42. 42.
    Levine LA, Larsen SM. Surgery for Peyronie’s disease. Asian J Androl. 2013;15(1):27–34.PubMedGoogle Scholar
  43. 43.
    Hatzichristodoulou G. Grafting techniques for Peyronie’s disease. Transl Androl Urol. 2016;5(3):334–41.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Anaissie J, Yafi FA. A review of surgical strategies for penile prosthesis implantation in patients with Peyronie’s disease. Transl Androl Urol. 2016;5(3):342–50.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Rice PG, Somani BK, Rees RW. Twenty years of plaque incision and grafting for Peyronie’s disease: a review of literature. Sex Med. 2019;7:115–28.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Levine LA, Burnett AL. Standard operating procedures for Peyronie’s disease. J Sex Med. 2013;10(1):230–44.PubMedGoogle Scholar
  47. 47.
    Kadioglu A, Akman T, Sanli O, Gurkan L, Cakan M, Celtik M. Surgical treatment of Peyronie’s disease: a critical analysis. Eur Urol. 2006;50(2):235–48.PubMedGoogle Scholar
  48. 48.
    Khera M, Bella A, Karpman E, Brant W, Christine B, Kansas B, et al. Penile prosthesis implantation in patients with Peyronie’s disease: results of the PROPPER study demonstrates a decrease in patient-reported depression. J Sex Med. 2018;15(5):786–8.PubMedGoogle Scholar
  49. 49.
    Hay DC, Louie DL, Earp BE, Kaplan FTD, Akelman E, Blazar PE. Surgical findings in the treatment of Dupuytren’s disease after initial treatment with clostridial collagenase (Xiaflex). J Hand Surg Eur Vol. 2014;39(5):463–5.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Henry Ford Health SystemVattikuti Urology InstituteDetroitUSA

Personalised recommendations